Expression of somatostatin receptor type-2 (sst2A) in immature porcine Leydig cells and a possible role in the local control of testosterone secretion.
We recently reported that immature porcine Leydig cells express both somatostatin (SRIF) and SRIF receptor type-2 (sst-2) transcripts. The present study was therefore undertaken to assess whether SRIF might exert autocrine actions on these cells through sst2A receptor, one of the two sst2 isoforms known to exert important neuroendocrine and endocrine functions. Using a polyclonal antibody directed towards the C-terminal tail of the sst2A receptor subtype, receptor immunoreactivity was detected in a subpopulation of Leydig cells and spermatogonia. To address the physiological correlates of this expression we then studied the possible involvement of sst2 receptor in the regulation of testosterone secretion. Functional assays showed that the sst2 agonist octreotide inhibited both basal and hCG-stimulated testosterone secretion by testosterone pretreated Leydig cells. To assess whether sst2 receptor expression might be regulated by testosterone, we performed a semi-quantitative RT-PCR analysis of sst2 mRNA expression in Leydig cells cultured in the presence or in the absence of the androgen. A significant increase in sst2 receptor transcripts was observed in testosterone-treated cells. Taken together, these data suggest that SRIF can inhibit testosterone secretion through the sst2A receptor. The mechanism of the local inhibitory actions of SRIF is probably autocrine since immature porcine Leydig cells express SRIF itself and it might involve testosterone-induced increase of sst2 receptor expression in immature Leydig cells.
Fombonne
Joanna
J
Institut National de la Santé et de la Recherche Médicale U-407, France. fombonne.j@jean-roche.univ-mrs.fr
Csaba
Zsolt
Z
von Boxberg
Ysander
Y
Valayer
Amandine
A
Rey
Catherine
C
Benahmed
Mohamed
M
Dournaud
Pascal
P
Krantic
Slavica
S
D000818:Animals; D019898:Autocrine Communication; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D007985:Leydig Cells / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D015282:Octreotide / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D017481:Receptors, Somatostatin / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013004:Somatostatin / Q000819:agonists / Q000096:biosynthesis / Q000502:physiology*; D013552:Swine / Q000502:physiology*; D013737:Testis / Q000166:cytology / Q000254:growth & development; D013739:Testosterone / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D012333:RNA, Messenger; D017481:Receptors, Somatostatin; C106140:somatostatin receptor sst2A; D013739:Testosterone; D013004:Somatostatin; D015282:Octreotide